Table 2. The distribution of EBNA1variants and EBV types in lymphomas, nasopharyngeal carcinomas, EBVaGCs and throat washing samples from healthy donors.
| Lymphoma(n = 110) | NPC(n = 41) | EBVaGC(n = 41) | TWs(n = 55) | |
|---|---|---|---|---|
| EBNA1 variants | ||||
| V-val | 75(68.2%) | 30 (73.2%) | 32 (78.0%) | 34 (61.8%) |
| P-thrV | 17(15.5%) | 10 (24.4%) | 5 (12.2%) | 15 (27.3%) |
| V-leuV | 4(3.6%) | 1 (2.4%) | 2 (4.9%) | 1 (1.8%) |
| P-ala | 12(10.9%) | 0 | 0 | 1 (1.8%) |
| V-val + P-ala | 2(1.8%) | 0 | 0 | 1 (1.8%) |
| V-val + P-thrV | 0 | 0 | 1 (2.4%) | 3 (5.5%) |
| V-val + V-leuV | 0 | 0 | 1 (2.4%) | 0 |
| EBV types | ||||
| Type 1 | 81(73.6%) | 34(82.9%) | 36(87.8%) | 41(74.5%) |
| Type 2 | 7(6.4%) | 7(17.1%) | 5(12.2%) | 12(21.8%) |
| Type1+2 | 22(20%) | 0 | 0 | 2(3.7%) |
NPCs: nasopharyngeal carcinomas; EBVaGCs: EBV-associated gastric carcinomas; TWs: throat washings from healthy donors.